NL-OMON24772RecruitingNot Applicable
Bezafibrate in X-linked adrenoleukodystrophy (X-ALD).
niversity of Amsterdam, Academic Medical Center, Department of Neurology and Department of Genetic Metabolic Diseases.0 sites10 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. An age of 18 years or older;
- •2. Capable of giving informed consent and physically capable of visiting the hospital for follow-up visits;
Exclusion Criteria
- •1. Use of medication that lowers cholesterol and/or triglycerides (e.g. statins);
- •2. Liver disease or and increase in serum CK of more than 3 times the baseline level;
Investigators
Similar Trials
Completed
Not Applicable
The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)X-linked AdrenoleukodystrophyAdrenomyeloneuropathyNCT01165060Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10
Not yet recruiting
Not Applicable
Phenotyping X-linked adrenoleukodystrophy (X-ALD) in women: a cohort studySchilder's disease1002742410041543X-linked adrenoleukodystrophyNL-OMON31235Academisch Medisch Centrum40
Recruiting
Not Applicable
Registry of X-linked AdrenoleukodystrophyX-linked AdrenoleukodystrophyNCT05939232Beijing Tiantan Hospital200
Completed
Phase 2
A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of AntioxidantsAdrenomyeloneuropathyNCT01495260Pujol, Aurora, M.D.13
Completed
Phase 2
Effect of Pioglitazone Administered to Patients With AdrenomyeloneuropathyAdrenomyeloneuropathyX-linked AdrenoleukodystrophyNCT03864523Pujol, Aurora, M.D.18